Isolating Induced Pluripotent Stem Cells by Using the WOLF G2 to Sort Stemness-Related Surface Markers
Gentle sorting of hiPSCs grown in HiDef-B8 medium
Gentle cell sorting technologies are advantageous in the isolation and expansion of homogeneous hiPSCs, as is the use of fully defined and animal-free cell media. In collaboration with NanoCellect Biomedical, we grew hiPSCs in HiDef-B8 and used the WOLF G2 to identify and enrich for hiPSCs expressing SSEA-4 and TRA-1-60-R. HiDef-B8 grown hiPSCs showed healthy morphology, viability, and expression of these markers, with robust post-sorting recovery in the same medium.
Development of FGF2 homologs for applications in human stem cell culture and the cultivated meat industry
FGF2 variants for life science and cultivated meat
Naturally occurring isoforms of growth factors offer a range of unique features across diverse applications, and suggest means for evolution-driven improvements in stability, function, and efficacy. We produced a range of FGF2 homologs, coupled with the structure determination of thermostable human variant FGF2-G3, to inform the development of new growth factor solutions. Presented at ISSCR 2022.
Defining Culture: Cost-effective Medium to Improve Stem Cell Reproducibility
Engineering approaches to medium optimization
Current growth medium solutions for the cell culture space are oftentimes inconsistent, variable, and costly, warranting the development of more optimized alternatives. We applied a design of experiments (DOE) to fit a response surface methodology (RSM) model to HiDef-B8 medium for continued optimization in stem cell culture. Presented at ISSCR 2022.
Growth factor production and optimization for fully-defined media in induced pluripotent stem cell culture
FGF2-G3 usage in HiDef-B8
Serum-containing media present major obstacles for the cell culture space, including batch-to-batch variability, undefined componentry, and the introduction of growth-inhibiting factors. We produced FGF2-G3, a thermostable variant of human FGF2, and studied its use in the context of HiDef-B8, a serum-free, fully-defined formulation for the culture of stem cells. Presented at ISSCR 2022.